title: Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma.
abstract: Pyruvate dehydrogenase A1 (PDHA1) serves as a gate-keeper enzyme link between glycolysis and the mitochondrial citric acid cycle. The inhibition of PDHA1 in cancer cells can result in an increased Warburg effect and a more aggressive phenotype in cancer cells. This study was conducted to investigate the expression of PDHA1 in ovarian cancer and the correlation between PDHA1 expression and the prognosis of patients. The PDHA1 protein expression in 3 ovarian cancer cell lines (OVCAR-3, SKOV-3 and ES-2) and 248 surgically removed ovarian carcinoma samples was immunocytochemically examined. Statistical analyses were performed to evaluate the correlations between PDHA1 expression and the clinicopathological characteristics of the patients as well as the predictive value of PDHA1. The results showed the presence of variable expression of PDHA1 in the three ovarian cancer cell lines. Of the 248 ovarian cancer tissue specimens, 45 cases (18.1%) were negative in tumor cells for PDHA1, 162 cases (65.3%) displayed a low expression level, and 41 cases (16.5%) had a relatively high PDHA1 staining. The expression of PDHA1 was associated with the histological subtype (P=0.004) and FIGO stage (P=0.002). The median OS time in the PDHA1 negative group, low expression group and high expression group were 0.939 years, 1.443 years and 9.900 years, respectively. The median PFS time in the above three groups were 0.287 years, 0.586 years and 9.900 years, respectively. Furthermore, the high expression of PDHA1 in ovarian carcinoma cells was significantly associated with better OS and PFS by statistical analyses. Multivariate analyses showed that PDHA1 expression was also an independent prognostic factor for higher OS in ovarian cancer patients (HR=0.705, 95% CI 0.541-0.918,P=0.01). Our study indicated that the decreased expression of PDHA1 might be an independent prognostic factor in unfavorable outcomes.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052, Henan Province, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway.
authors.forename: Yaqing
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
authors.forename: Ruixia
authors.initials: R
authors.lastname: Huang
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052, Henan Province, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
authors.forename: Xiaoran
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052, Henan Province, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway.
authors.forename: Dandan
authors.initials: D
authors.lastname: Yu
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan Province, China.
authors.forename: Mingzhi
authors.initials: M
authors.lastname: Zhang
authors.affiliation: The Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan Province, China.
authors.forename: Jianguo
authors.initials: J
authors.lastname: Wen
authors.affiliation: Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of Oslo Montebello, Oslo 0379, Norway.
authors.forename: Mariusz Adam
authors.initials: MA
authors.lastname: Goscinski
authors.affiliation: Department of Gynecology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway; Department of Gynecology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
authors.forename: Claes G
authors.initials: CG
authors.lastname: Trope
authors.affiliation: Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
authors.forename: Jahn M
authors.initials: JM
authors.lastname: Nesland
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052, Henan Province, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
authors.forename: Zhenhe
authors.initials: Z
authors.lastname: Suo
keywords: Pyruvate dehydrogenase A1; immunohistochemical analysis; ovarian carcinoma; prognosis